The world is facing a critical challenge in the realm of healthcare, and it's time to sound the alarm. As we observe World Antimicrobial Resistance (AMR) Awareness Week, a recent study has unveiled a worrying trend: a dangerous imbalance between falling prices and rising costs, coupled with shortages of essential medicines. This crisis demands our immediate attention and action.
The study, conducted by New Angle and presented by Viatris and Medicines for Europe, delves into the reasons behind the shortages of off-patent medicines, particularly antibiotics. The findings are eye-opening and highlight the urgent need for reform in national pricing and procurement systems.
Here are the key takeaways:
- From 2020 to 2024, the average price of the top 10 off-patent antibiotics dropped by a significant 10.4%, while production costs and inflation skyrocketed. This means that manufacturers are facing a challenging economic landscape.
- Industrial producer costs surged by 31.6%, labor costs by 25.7%, and energy prices by a staggering 88% for gas and 62% for electricity. These increases put immense pressure on the production of essential medicines.
- Despite the price drop, amoxicillin, a commonly used antibiotic, saw its prices decrease by 18.9%. This highlights the impact of market forces on essential medicines.
- A staggering 240 antibiotic medicines were withdrawn from the market, and 385 shortages were reported across 16 European countries. These shortages directly impact patient access and healthcare outcomes.
But here's where it gets controversial: the current pricing and procurement rules are leading to a situation where the economic viability of producing these critical medicines is at risk. Without reforms, we might witness a scenario where patients across Europe lose access to life-saving treatments, which could have devastating consequences for public health and accelerate antimicrobial resistance.
So, what can be done? Viatris and Medicines for Europe propose urgent policy reforms to support the economic viability and availability of off-patent medicines. These include price indexation to inflation and production costs, minimum price policies to prevent short-term savings from limiting availability, and tiered pricing models to encourage healthy market competition.
Additionally, they advocate for procurement reform, suggesting multi-winner tenders and considering non-price criteria like supply reliability and environmental standards.
The implications of this study are far-reaching, especially as institutions worldwide mark World AMR Awareness Week. Viatris, for instance, underscores the importance of its broader AMR efforts, from cross-sector collaborations to institutional alignments. These initiatives aim to protect patient access to essential antibiotics and other off-treatments, ensuring their availability despite sustainability challenges.
Viatris and Medicines for Europe call on policymakers, healthcare leaders, and industry partners to take action based on the study's evidence. The time to build sustainable systems that secure access to essential antibiotics is now.
Read the full study on the Viatris website or with Medicines for Europe to delve deeper into the findings and explore potential solutions. The future of antibiotic availability and patient access depends on it.
Let's spark a conversation: Do you think the proposed policy reforms are enough to address the challenges highlighted in the study? What other steps do you believe are necessary to ensure sustainable access to essential medicines?
